公开(公告)号：US20240010731A1

公开(公告)日：2024-01-11

申请号：US18328707

申请日：2023-06-02

Applicant: Debiopharm International S.A. ,  Merck Patent GmbH ,  Pfizer Inc.

Inventor： Grégoire Vuagniaux ,  Norbert Wiedemann ,  Claudio Zanna

IPC: A61K31/407 ,  A61K39/395 ,  A61P35/00

CPC classification number: A61K31/407 ,  A61K39/3955 ,  A61P35/00

Abstract: Methods of administering a therapeutically effective amount of Debio 1143 and a therapeutically effective amount of an anti-PD-L1 antibody or antigen-binding fragment thereof, for the treatment of cancer, are provided.

公开(公告)号：US20240010696A1

公开(公告)日：2024-01-11

申请号：US18335259

申请日：2023-06-15

Applicant: Pfizer Inc.

Inventor： James Reasoner APGAR ,  Javier Fernando CHAPARRO RIGGERS ,  Ling Hon Matthew CHU ,  Tzu-Hsuan HUANG ,  Kritika MOHAN ,  Lidia MOSYAK ,  Edward Derrick PASCUA ,  James Travis PATTERSON ,  Gabriel Roy STARBECK-MILLER ,  Dirk Michael ZAJONC

IPC: C07K14/54 ,  C07K16/28 ,  A61P35/00 ,  C12N15/63

CPC classification number: C07K14/5434 ,  C07K16/2818 ,  A61P35/00 ,  C12N15/63 ,  C07K2317/565

Abstract: IL-12 variants are provided. Also provided are antibodies that specifically bind to PD1. Also provided are fusion proteins of IL-12 variants and anti-PD1 antibodies. Also provided are uses of these IL-12 variants, anti-PD1 antibodies, fusion proteins, and related compositions and methods.

公开(公告)号：US20240009296A1

公开(公告)日：2024-01-11

申请号：US18347698

申请日：2023-07-06

Applicant: PFIZER INC.

Inventor： Hui Cai ,  Ye Che ,  Fernando Martin Diaz ,  Raquel Munoz-Moreno ,  Alicia Solórzano Quijano ,  Chong Wang

IPC: A61K39/145

CPC classification number: A61K39/145 ,  A61K2039/53

Abstract: Self-amplifying RNA (saRNA) molecules encoding an influenza virus antigen and methods of use thereof are disclosed herein.

公开(公告)号：US20230414522A1

公开(公告)日：2023-12-28

申请号：US18036141

申请日：2021-11-11

Applicant: PFIZER INC.

Inventor： Alan Francis CARMODY ,  Lydie Claude Sylvie PAIRET

IPC: A61K9/48 ,  A61K47/10 ,  A61K47/26 ,  A61K47/22 ,  A61K31/5025 ,  A61P35/00

CPC classification number: A61K9/4825 ,  A61K47/10 ,  A61K47/26 ,  A61K47/22 ,  A61K31/5025 ,  A61P35/00

Abstract: A pharmaceutical soft gelatin capsule dosage form comprising a soft gelatin shell and a fill, wherein: (a) the soft gelatin shell comprises gelatin and at least one plasticizer; and (b) the fill comprises an anti-oxidant, at least one solvent, and talazoparib or a pharmaceutically acceptable salt thereof. Said pharmaceutical composition for use in treating cancer.

公开(公告)号：US11845732B2

公开(公告)日：2023-12-19

申请号：US18170884

申请日：2023-02-17

Applicant: Pfizer Inc.

Inventor： Elaine Greer ,  Stephen Anderson ,  Mark Maloney ,  Shu Yu ,  Ekaterina Albert ,  Emily Rigsbee

IPC: A61K31/40 ,  C07D233/88

CPC classification number: C07D233/88 ,  A61K31/40 ,  C07B2200/13

Abstract: The present disclosure relates to: a) solid state forms of hydrobromide salts of Compound 1; b) pharmaceutical compositions comprising one or more solid state forms of hydrobromide salts of Compound 1, and, optionally, a pharmaceutically acceptable carrier; c) methods of treating tumors or cancers by administering one or more solid state forms of hydrobromide salts of Compound 1 to a subject in need thereof; and d) methods for the preparation of solid state forms of Compound 1.

公开(公告)号：US20230398129A1

公开(公告)日：2023-12-14

申请号：US18250570

申请日：2021-10-26

Applicant: Pfizer Inc.

Inventor： Christopher Lee Beltz

IPC: A61K31/569 ,  A61K47/14 ,  A61K47/10 ,  A61K47/44 ,  A61K9/08 ,  A61K9/00

CPC classification number: A61K31/569 ,  A61K47/14 ,  A61K47/10 ,  A61K47/44 ,  A61K9/08 ,  A61K9/0019

Abstract: A pharmaceutical formulation for parental use comprising testosterone cypionate with a concentration of 200 mg/mL, benzyl benzoate with a concentration of 25%-35% v/v, cottonseed oil, and a preservative. A pharmaceutical product comprising a vial containing said formulation. A kit which comprises said pharmaceutical product and a package insert that is free of instructions to warm and shake the vial.

公开(公告)号：US20230390307A1

公开(公告)日：2023-12-07

申请号：US18249581

申请日：2021-10-19

Applicant: Pfizer Inc.

Inventor： Omar Abdelrahman Salman ,  Joel Aaron Bergman

IPC: A61K31/573 ,  A61K47/22 ,  A61K31/57 ,  A61K9/10

CPC classification number: A61K31/573 ,  A61K47/22 ,  A61K31/57 ,  A61K9/10

Abstract: A parenteral aqueous suspension formulation for corticosteroids without polyethylene glycol (PEG) or Polysorbate (PS) that has better resuspendability, longer stability compared to commercially available formulations, and additionally allows for stable formulations of higher concentrations of corticosteroids that were not previously feasible. Preferably, the corticosteroid is methylprednisolone acetate or medroxyprogesterone acetate.

公开(公告)号：US20230365701A1

公开(公告)日：2023-11-16

申请号：US18315054

申请日：2023-05-10

Applicant: Pfizer Inc.

Inventor： James Reasoner APGAR ,  Bas Joannes Gertrudis BAATEN ,  Aruna BITRA ,  Javier Fernando CHAPARRO RIGGERS ,  Giuseppe DI CARO ,  Pawel Kamil DOMINIK ,  Zachary John MABEN ,  Lidia MOSYAK ,  Andrew Ross NAGER ,  Cecilia Marianne ODERUP ,  Edward Derrick PASCUA ,  Shahram SALEK-ARDAKANI ,  Dirk Michael ZAJONC

IPC: C07K16/28 ,  A61P35/00

CPC classification number: C07K16/2878 ,  A61P35/00 ,  C07K2317/35 ,  C07K2317/71 ,  C07K2317/92 ,  A61K2039/505

Abstract: Antibodies that specifically bind to LTBR are provided. Also provided are uses of these antibodies, and related compositions and methods.

公开(公告)号：US20230346903A1

公开(公告)日：2023-11-02

申请号：US18060779

申请日：2022-12-01

Applicant: Pfizer Inc.

Inventor： Annaliesa Sybil Anderson ,  Amardeep Singh Bhupender Bhalla ,  Robert G.K. Donald ,  Jianxin Gu ,  Kathrin Ute Jansen ,  Rajesh Kumar Kainthan ,  Lakshmi Khandke ,  Jin-Hwan Kim ,  Paul Liberator ,  Avvari Krishna Prasad ,  Mark Edward Ruppen ,  Ingrid Lea Scully ,  Suddham Singh ,  Cindy Xudong Yang

IPC: A61K39/09 ,  C07K16/12 ,  C07K16/44 ,  A61K39/39 ,  A61K39/40 ,  A61K47/10 ,  A61K47/26

CPC classification number: A61K39/092 ,  C07K16/1275 ,  C07K16/44 ,  A61K39/39 ,  A61K39/40 ,  A61K47/10 ,  A61K47/26 ,  A61K2039/505

Abstract: The invention relates to immunogenic polysaccharide-protein conjugates comprising a capsular polysaccharide (CP) from Streptococcus agalactiae, commonly referred to as group B streptococcus (GBS), and a carrier protein, wherein the CP is selected from the group consisting of serotypes Ia, Ib, II, III, IV, V, VI, VII, VIII, and IX, and wherein the CP has a sialic acid level of greater than about 60%. The invention also relates to methods of making the conjugates and immunogenic compositions comprising the conjugates. The invention also relates to immunogenic compositions comprising polysaccharide-protein conjugates, wherein the conjugates comprise a CP from GBS serotype IV and at least one additional serotype. The invention further relates to methods for inducing an immune response in subjects against GBS and/or for reducing or preventing invasive GBS disease in subjects using the compositions disclosed herein. The resulting antibodies can be used to treat or prevent GBS infection via passive immunotherapy.

公开(公告)号：US11802156B2

公开(公告)日：2023-10-31

申请号：US17338991

申请日：2021-06-04

Applicant: Pfizer Inc.

Inventor： Karin Anderson

IPC: C07H21/04 ,  C12P21/06 ,  C12N1/20 ,  C12N15/74 ,  C07K16/28 ,  A61P29/00 ,  A61P37/06 ,  A61K39/00

CPC classification number: C07K16/2803 ,  A61P29/00 ,  A61P37/06 ,  A61K2039/505 ,  C07K16/2839 ,  C07K2317/21 ,  C07K2317/33 ,  C07K2317/40 ,  C07K2317/52 ,  C07K2317/56 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2317/94

Abstract: The present disclosure relates to antibodies including human antibodies and antigen-binding portions thereof that specifically bind to MAdCAM, preferably human MAdCAM and that function to inhibit MAdCAM. The disclosure also relates to human anti-MAdCAM antibodies and antigen-binding portions thereof. The disclosure also relates to antibodies that are chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The disclosure also relates to isolated heavy and light chain immunoglobulins derived from human anti-MAdCAM antibodies and nucleic acid molecules encoding such immunoglobulins. The present disclosure also relates to methods of making human anti-MAdCAM antibodies, compositions comprising these antibodies and methods of using the antibodies and compositions for diagnosis and treatment. The disclosure also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-MAdCAM antibodies. The disclosure also relates to transgenic animals or plants comprising nucleic acid molecules of the disclosure.